Magic RNA

Based in Shenzhen, China and founded in 2021, Shenzhen MagicRNA Biotech Co. , Ltd. , trading as Magic RNA, operates as a biotechnology company dedicated to developing RNA drugs. It has applied for more than ten invention patents, including multiple PCT and European and American invention patents, of which 4 patents have been authorized.

The company cooperated with Sun Yat-sen University Affiliated Hospital, West China Hospital and other hospitals in the fields of urology, gynecological oncology and other fields. In December 2025, Magic RNA raised a series A funding from new investors MPC, Tencent Investment, returning investor IDG Capital and other investors. The company engages in the R&D of mRNA drugs for gynaecological diseases and urinary system tumours, based on the self-development of three technology platforms, including the mRNA sequence design platform, mRNA synthesis platform, and lipid nanoparticles (LNP) delivery platform. The company has product lines such as infectious disease mRNA vaccines, mRNA tumor vaccines, and protein replacement therapies.

Magic RNA developed Engineered Cell Targeted LNPs (EnC-LNPs) platform, which provides solutions for extrahepatic delivery of nucleic acid drugs. The company's first tumor therapeutic drug HN2201 has completed preclinical development. The company's revenue is generated by providing mRNA and circular RNA products, custom mRNA synthesis, and LNP encapsulation services to biotech and pharmaceutical clients.